These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32488887)

  • 1. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
    Wallenhorst C; Patel A; Shebl A; Hubsch A; Simon TL; Martinez C
    Transfusion; 2020 Jul; 60(7):1381-1390. PubMed ID: 32488887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
    Shebl A; Gabriel S; Van Dinther K; Hubsch A; Lawo JP; Hoefferer L; Welsh S
    Transfusion; 2020 Jun; 60(6):1278-1286. PubMed ID: 32410287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
    Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
    Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
    Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
    BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
    Siani B; Willimann K; Wymann S; Marques AA; Widmer E
    Biol Ther; 2014 Dec; 4(1-2):15-26. PubMed ID: 24841428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
    Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
    Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
    Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
    McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W
    Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study.
    Martinez C; Wallenhorst C; van Nunen S
    Clin Exp Immunol; 2021 Dec; 206(3):384-394. PubMed ID: 34562316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
    Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
    J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.
    Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB
    Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
    Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
    Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.
    Ucar İ; Koyuncu MB; Solmaz AA; Ugurludogan AC; Mercan S; Kucuk M; Unal T; Mazman S; Atilla E
    Transfus Clin Biol; 2023 Feb; 30(1):11-15. PubMed ID: 36028153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.
    Bürzle M; Hubsch A; Spiegl N; Roten T; Marques A; Martig L; Shebl A; Stadler D
    Anal Biochem; 2020 Feb; 591():113534. PubMed ID: 31821802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.